Current Opinion in Allergy and Clinical Immunology
Allergen Specific Immunotherapy for Atopic Dermatitis CME

Disclosures

Release Date: January 15, 2008; Valid for credit through January 15, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Atopic dermatitis affects up to 20% of children and 3% of adults, and sensitizations to allergens can increase dermatitis symptoms. The current review examines the potential role for allergen-specific immunotherapy in the management of atopic dermatitis.

  1. Allergen Specific Immunotherapy for Atopic Dermatitis
    Natalija Novak, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the relationship between allergens and atopic dermatitis
  2. List the immunologic effects of immunotherapy
  3. Identify clinical outcomes of allergen-specific immunotherapy in the management of atopic dermatitis
Authors and Disclosures

Natalija Novak, MD
Disclosure: Natalija Novak, MD, has disclosed that she has grant support from the German Research Council and Bonfas as well as from Bencard Allergie GmbH and LETI Pharma GmbH. Dr. Novak has also disclosed that she is on the advisory board for Novartis and LETI Pharma GmbH.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.